This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Cosentyx
  • /
  • A Three-part Randomized, Double-blind, Placebo-con...
Clinical trial

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

Read time: 2 mins
Last updated:15th Mar 2017
Identifier: NCT03031782
This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study is divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2.

 

Category Value
Date last updated at source 2017-02-07
Study type(s) Interventional
Expected enrolment 80
Study start date 2017-03-15
Estimated primary completion date 2020-12-30

View full details